BRIEF-Peregrine Pharma up in premarket after internal review of phase II lung cancer trial

NEW YORK Mon Jan 7, 2013 8:47am EST

NEW YORK Jan 7 (Reuters) - Peregrine Pharmaceuticals Inc : * Peregrine Pharma up 31.1 percent to $1.77 in premarket after an update of its internal review of the phase II second-line non-small call lung cancer trial

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.